Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates

Pediatric Pulmonology

Volumn 35, Issue 2, 2003, Pages 99-107

  Cantón, Rafael ^a   Valdezate, Sylvia ^a,b   Vindel, Ana ^b   Sánchez Del Saz, Begoña ^a   Maíz, Luis ^a   Baquero, Fernando ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antimicrobial resistance; Cystic fibrosis; Pulsed field gel electrophoresis; Stenotrophomonas maltophilia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CLAVULANIC ACID; CLINAFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; LATAMOXEF; MINOCYCLINE; MOXIFLOXACIN; PIPERACILLIN; TICARCILLIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CYSTIC FIBROSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; RESPIRATORY SYSTEM; STENOTROPHOMONAS MALTOPHILIA;

EID: 0037318074     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10216     Document Type: Article

References (38)

1. Lees CM, Smyth RL. The current management of cystic fibrosis. Int J Clin Pract 2000;54:171-179.
2. Denton M. Stenotrophomonas maltophilia: an emerging problem in cystic fibrosis patients. Rev Med Microbiol 1997;8:15-19.
3. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163.
4. Demko CA, Stem RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol 1998;25:304-308.
5. Lecso-Bornet M, Pierre J, Sarkis-Karam D, Lubera S, Bergogne-Berezin E. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother 1992;36: 669-671.
6. Denton M, Wilcox MH. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother 1997;40:468-474.
7. Cheng AF, Li MW, Ling TKW, French GL. Emergence of ofloxacin-resistant Citrobacter freundii and Pseudomonas maltophilia after ofloxacin therapy. J Antimicrob Chemother 1987; 20:283-285.
8. Alonso A, Martínez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41:1140-1142.
9. Zhang L, Xian-Zhi L, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 2000;44:287-293.
10. Lambert T, Ploy MC, Denis F, Courvalin P. Characterization of the chromosomal aac(6′)-Iz gene of Stenothrophomonas maltophilia. Antimicrob Agents Chemother 1999;43:2366-2361.
11. Denton M, Kerr KG. Microbiology and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57-80.
12. Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001;45:413-419.
13. Valdezate S, Vindel A, Máiz L, Baquero F, Escobar H, Cantón R. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients. Emerg Infect Dis 2001;7:113-122.
14. Wong K, Roberts MC, Owens L, Fife M, Smith AL. Selective media for the quantification of bacteria in cystic fibrosis sputum. J Med Microbiol 1984;17:113-119.
15. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol 1998;36: 1953-1958.
16. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33: 2233-2239.
17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; eleventh informational supplement. M100-S11 Wayne, PA: NCCLS; 2001.
18. Lecso-Bonet M, Bergone-Bérézin E. Susceptibility of 100 strains of Stenotrophomonas maltophilia to three β-lactams and five β-lactam-β-lactamase inhibitor combinations. J Antimicrob Chemother 1997;40:717-720.
19. Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos (MENSURA). Recomendaciones del grupo MENSURA para la selección de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretación del antibiograma. Rev Esp Quimioter 2000;13:73-86.
20. Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol 1988;26:2465-2466.
21. Talamaciu I, Varlotta L, Mortensen J. Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000;30:10-15.
22. Hauben L, Vauterin L, Moore ER, Hoste B, Swings J. Genomic diversity of the genus Stenothrophomonas. Int J Syst Bacteriol 1999;49:1749-1760.
23. Heinemann B, Wisplingoff H, Edmond M, Seifert H. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains. Antimicrob Agents Chemother 2000;44:2211-2213.
24. Muñoz-Bellido JL, Muñoz-Criado S, García-García I, Alonso-Manzanares MA, Gutiérrez-Zufiaurre MN, García-Rodríguez JA. In vitro activities of β-lactam-β-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity. Antimicrob Agents Chemother 1997; 41: 2621-2615.
25. Elkhaili H, Pompei D, Linger L, Kamili N, Jehl F. Cinetique de bactericidie de cefepime et cefpirome seuls ou associés à la gentamicine, amikacine ou ciprofloxacine sur Acinetobacter baumanii, Stenotrophomonas maltophilia et Enterobacter cloacae hyperproducteur de cephalosporinase. Pathol Biol 1996;44:367-373.
26. Schmitz FJ, Sadurski R, Verhoef J, Milatovic D, Fluit AC, European SENTRY participants. Typing of 154 clinical isolates of Stenotrophomonas maltophilia by pulsed-field gel electrophoresis and determination of the in vitro susceptibilities of these strains to 28 antibiotics. J Antimicrob Chemother 2000;45:921-924.
27. Shawar RM, MacLeod DL, Garber RL, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43:2877-2880.
28. Mooney L, Kerr KG, Denton M. Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients. Int J Antimicrob Agents 2001;17:63-66.
29. Westbrock-Wadman S, Sherman DR, Hickey M, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 1999;43:2975-2983.
30. Howe RA, MacGowan AP. The effect of macrolide antibiotics of biofilm formation by Stenotrophomonas maltophilia. J Antimicrob Chemother [Suppl] 1999;44:68-69.
31. Pankuch GA, Jacobs MR, Applebaum PC. Susceptibilities of 123 strains of Xanthomonas maltophilia to clinafloxacin, PD131628, PD138312, PD140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother 1994;38:369-370.
32. Biedenbach DJ, Crocoi MAT, Barrett TJ, Jones RN. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. Eur J Clin Microbiol Infect Dis 1999;18:428-431.
33. Visalli MA, Jacobs MR, Appelbaum PC. Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1998;42:2002-2005.
34. Valdezate S, Vindel A, Baquero F, Cantón R. Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 1999;18:908-911.
35. Weiss K, Restieri C, De Carolis E, Laverdiére M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of S. maltophilia. J Antimicrob Chemother 2000;45:363-365.
36. Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, Painter BG, Thurberg BE, Haverstock DC, Perroncel RY, Echols RM. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/ tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16: 97-105.
37. Kurlandsky LE, Fader RC. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis. Pediatr Pulmonol 2000;29:210-212.
38. Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulphamethoxazole: a study of 69 patients at two university hospitals. Scand J Infect Dis 2000; 32:651-656.